Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective
暂无分享,去创建一个
M. Miravitlles | I. Naya | Y. Asukai | N. Risebrough | F. García-Río | J. Whalen | M. Driessen | B. Seewoodharry Buguth | L. Vallejo-Aparicio | B. Alcázar-Navarrete
[1] M. Miravitlles,et al. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis , 2017, Respiratory Research.
[2] J. Riley,et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study , 2017, Advances in Therapy.
[3] A. Huerta,et al. Cost-Effectiveness Analysis Of Two Long-Acting Muscarinic Antagonists For Copd Treatment In Spain: Umeclidinium VS. Tiotropium (HO-17-18472) , 2017 .
[4] I. Oyagüez,et al. Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain , 2017 .
[5] A. Ismaila,et al. A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD , 2017, Pulmonary Therapy.
[6] M. Miravitlles,et al. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study , 2017, International journal of chronic obstructive pulmonary disease.
[7] J. Soriano,et al. Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease , 2017 .
[8] Pere Almagro,et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable , 2017 .
[9] A. Ismaila,et al. Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.
[10] A. Briggs,et al. Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.
[11] A. Ismaila,et al. Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.
[12] M. Roset,et al. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study , 2017, International journal of chronic obstructive pulmonary disease.
[13] R. Stanford,et al. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model , 2017, International journal of chronic obstructive pulmonary disease.
[14] Reiner Leidl,et al. External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] E. Kerwin,et al. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study , 2017, International journal of chronic obstructive pulmonary disease.
[16] E. Ota,et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). , 2017, The Cochrane database of systematic reviews.
[17] J. Soriano,et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study , 2017, International journal of chronic obstructive pulmonary disease.
[18] H. Chrystyn,et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices , 2016, npj Primary Care Respiratory Medicine.
[19] A. Tebboth,et al. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD , 2016, ClinicoEconomics and outcomes research : CEOR.
[20] H. Chrystyn,et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries , 2016, BMC Health Services Research.
[21] A. Church,et al. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.
[22] M. Cazzola,et al. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.
[23] F. Maltais,et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.
[24] C. Micheletto,et al. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues , 2016, International journal of chronic obstructive pulmonary disease.
[25] Dave Singh,et al. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. , 2016, Respiratory medicine.
[26] M. Miravitlles,et al. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients , 2016, International journal of chronic obstructive pulmonary disease.
[27] Dave Singh,et al. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial , 2015, BMC Pulmonary Medicine.
[28] A. Church,et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. , 2015, Respiratory medicine.
[29] Sally J. Singh,et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials , 2014, Therapeutic advances in respiratory disease.
[30] N. Richard,et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. , 2014, Respiratory medicine.
[31] A. Ismaila,et al. Validating A Model To Predict Disease Progression Outcomes In Patients With COPD. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[32] M. Miravitlles,et al. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems , 2014, Health and Quality of Life Outcomes.
[33] P. Poole,et al. Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[34] E. Kerwin,et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.
[35] Ciro Casanova,et al. Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study , 2014, PloS one.
[36] A. Church,et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.
[37] D. Tashkin,et al. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.
[38] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[39] M. R. Rutten-van Mölken,et al. Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease , 2012, PharmacoEconomics.
[40] J. Soriano,et al. Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD , 2012 .
[41] Mario Cazzola,et al. Pharmacology and Therapeutics of Bronchodilators , 2012, Pharmacological Reviews.
[42] M. Miravitlles,et al. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable , 2012 .
[43] A. Briggs,et al. Predicting EQ-5D values using the SGRQ. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[44] J. Soriano,et al. [Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors]. , 2010, Archivos de bronconeumologia.
[45] Edwin K Silverman,et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.
[46] Anna García-Altés,et al. Spanish recommendations on economic evaluation of health technologies , 2010, The European Journal of Health Economics.
[47] M. Decramer,et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.
[48] J. Soriano,et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities , 2009, Thorax.
[49] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[50] C. Lenfant,et al. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .
[51] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[52] M. Miravitlles,et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional , 2004 .
[53] M. Miravitlles,et al. [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study]. , 2004, Archivos de bronconeumologia.
[54] C. Cooper,et al. The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.
[55] Ramon Gisbert,et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. , 2003, Chest.
[56] P Stein,et al. The Consumer Price Index (CPI). , 1992, Trends & techniques in the contemporary dental laboratory.